Navigation Links
Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.


Michael S. Singer, M.D., Ph.D.
Contributing Editor
Harvard Medical School

The FDA approval of BiDil for heart failure in African American patients has underscored the concept that two patients can respond differently to the same medication. This concept holds true for a wide variety of everyday medications, and in many cases is due to individual genetic variations. As the field of pharmacogenetics focuses on these issues, valuable new laboratory tools have arrived to help clinicians apply pharmacogenetic knowledge to patient care.

Probably the most important gene family to govern individual drug responses, CYP (also called cytochrome P450) oxidases are a diverse family of enzymes that metabolize compounds unfamiliar to the body. Concentrated in liver cells, they modify the chemical structure of drugs shortly after they are absorbed from the gastrointestinal tract. The chemical modification renders them more water soluble and hence more easily excreted. Six CYP enzymes (named 1A2, 2C9, 2C19, 2D6, 2E1, 3A4) account for over 90% of drug metabolism (but do not appear to account for the selectivity of BiDil). Since a patient can take several concurrent medications metabolized by the same CYP enzyme, it should come as no surprise that CYP-related drug interactions are common. Clinicians are generally aware of these interactions, which either involve inhibition (competition) between two or more medications for the same enzyme, or induction (increase) of a particular CYP enzymes activity in response to a particular medication. In the former scenario, blood concentrations and the risk of side effects can rise to perilous levels; in the latter, concentrations can decline to the point that therapeutic value is lost.

Patients can also carry mutations or duplications in one or more CYP enzymes. Usually unbeknownst to the clinician, these polymorphisms can have pronounced effects on a patients ability to met abolize particular medications. As a result, patients can be classified as poor, intermediate, extensive, or ultra-rapid metabolizers. These conditions are relatively common, with prevalences that vary across different races. Similar to the scenarios described above, these patients are at risk for abnormal blood concentrations: poor metabolizers may develop serious side effects, and extensive or ultra-rapid metabolizers may be insufficiently treated.

Recent advances in microarray (gene chip) technology have made it possible to screen patients thoroughly for genetic variations in CYP enzymes. The AmpliChip CYP450 Test (Roche Diagnostics) detects mutations in two important CYP subtypes. The first, CYP2D6, metabolizes a number of medications, including antidepressants, anti-psychotics, anti-arrhythmics, and beta-blockers. The second, CYP2C19, metabolizes anticoagulants, anticonvulsants, proton pump inhibitors, benzodiazepines, anti-malarials, and other medications. The literature has shown that a genotype screen, such as the AmpliChip CYP 450 Test, can detect up to 90% of poor metabolizers at risk for overdoses.

High density microarrays, such as the one used by the AmpliChip CYP450 test, provide a versatile, miniaturized means to screen for multiple nucleic acid products in a rapid and parallel fashion. To build the microarray, small DNA fragments, also called probes, are anchored and synthesized at specific locations on a small, coated quartz surface. Different probes can be attached to different locations. Each probe is chosen to hybridize selectively with a specific DNA fragment. In the case of AmpliChip CYP450 test, this provides the ability for particular probes to bind portions of wild-type or mutant sequences from CYP2D6 and CYP2C19. The microarray is also constructed in a way that can detect duplications of a particular allele.

The actual test is carried out with a patient blood sample. The first step is to amplify CYP2D6 an d CYP2C19 gene products, which are then applied to the AmpliChip microarray and hybridized. The microarray is then washed, stained, and finally scanned. Computer software then interprets the optical pattern on the scan, which indicates the particular probes bound by the patients DNA sample. The software can then determine the patients genotype and predict a phenotype.

The GeneChip System 3000Dx (Roche Diagnostics) is a dedicated microarray system that supports the AmpliChip CYP450 Test. It includes a fluidics system, microarray scanner, workstation and software to carry out all of the steps outlined above. Other compatible products microarrays are expected in the future from Roche Diagnostics and its partner, Affymetrix. Companies such as Nanogen also continue to develop a number of microarray-based tools. Together, these advances will make tailored drug therapy a reality, and patients will benefit from more consistent phamacodynamics with fewer side effects.
'"/>




Related medicine technology :

1. Fast, Accurate Influenza A/B Antigen Detection
2. New Assays to Detect Disseminated Fungal Infections

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):